Choosing the Right API CDMO

PDF 200 kB

COVID-19 has put unprecedented demands on API manufacturers, exemplified by the dramatically increased need for drugs used to manage critical respiratory care patients being placed on mechanical ventilation.
In turn, this sudden requirement to significantly boost production has emphasized the importance of adaptability for API CDMOs to maintain drug supply, with some organizations proving better able than others to handle the pressures of rapid scale up.

Content provided by our supplier

Wavelength Pharmaceuticals

IL
2018

On CPHI since
2

Certificates
250 - 499

Employees

Company types

Contract Service

Manufacturer/Innovator

Other Content from Wavelength Pharmaceuticals (6)

Sponsored Content Biocatalysis: An Indispensable Tool for Synthesis of Active Pharmaceutical Ingredients

Biocatalytic processing offers a wealth of advantages and should be evaluated during early-stage drug development for its potential to improve yields, increase efficiency, and support greener manufacturing.

30 Sep 2021
Brochure Wavelength Pharma Company Presentation

Wavelength is commitment to be ‘Always Aligned’ with its customers’ needs, provides an exceptional value to hundreds of customers worldwide in an ever-changing and increasingly competitive global pharmaceutical market. Building upon a long heritage of excellence, and global leadership in select molecules, Wavelength has all the required capabilities and flexibility to reliably meet shifting customer needs and accommodate their growth. Learn more about our API development and manufacturing services.
Brochure API CDMO Services

A Trusted API CDMO Partner
Brochure Wavelength Pharmaceutical Product Catalog

See our latest product catalog
Brochure Wavelength Pharmaceutical Intermediates Product Catalog

See our latest list of intermediates
Video Wavelength Pharmaceuticals Introduction